Tomoko Yasuhiro

AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill <i>FLT3</i>-ITD acute myeloid leukemia

Sean M. Post, Huaxian Ma, Prerna Malaney et al. · Haematologica · 2021 · 32 citations · Full text

Medicine, Oncology, Pharmacology +16

Anti-tumor efficacy study of the Bruton’s tyrosine kinase (BTK) inhibitor, ONO/GS-4059, in combination with the glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab (GA101) demonstrates superior<i>in vivo</i>efficacy compared to ONO/GS-4059 in combination with rituximab

Tomoko Yasuhiro, Wako Sawada, Christian Klein et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2016 · 21 citations

Medicine, Oncology, Pharmacology +17

Triple combination therapy comprising osimertinib, an AXL inhibitor, and an FGFR inhibitor improves the efficacy of EGFR-mutated non-small cell lung cancer

Ryota Nakamura, Tadaaki Yamada, Shinsaku Tokuda et al. · Cancer Letters · 2024 · 20 citations · Full text

Medicine, Oncology, Pharmacology +17

Abstract 2021: ONO-WG-307, a novel, potent and selective inhibitor of Bruton's tyrosine kinase (Btk), results in sustained inhibition of the ERK, AKT and PKD signaling pathways

Tomoko Yasuhiro, Toshio Yoshizawa, Henrik Daub et al. · Cancer Research · 2012 · 17 citations

Life Sciences, Immunology, Pharmacology +17

Investigation of the anti-tumor mechanism of tirabrutinib, a highly selective Bruton’s tyrosine kinase inhibitor, by phosphoproteomics and transcriptomics

Ryohei Kozaki, Tomoko Yasuhiro, Hikaru Kato et al. · PLoS ONE · 2023 · 17 citations · Full text

Medicine, Oncology, Pharmacology +17